AstraZeneca taps Chinese biotech in $5.2bn chronic disease research deal

finance.yahoo.com/news/astrazeneca-taps-chinese-biotech-5-161930037.html

In This Article:
AstraZeneca has joined the long list of big pharma companies enlisting the services of Chinese biotechs, signing a deal worth up to $5.2bn with CSPC Pharmaceuticals to research chronic disease drug candidates.
Under the deal, AstraZeneca will pay an upfront fee of $110m,…

This story appeared on finance.yahoo.com, 2025-06-13 16:19:30.
The Entire Business World on a Single Page. Free to Use →